Enliven Therapeutics (NASDAQ:ELVN) Trading 7.5% Higher

Enliven Therapeutics, Inc. (NASDAQ:ELVN) traded up 7.5% during trading on Monday . The stock traded as high as $18.63 and last traded at $18.47. 88,659 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 228,233 shares. The stock had previously closed at $17.18.

Analyst Ratings Changes

Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target on the stock.

Enliven Therapeutics Stock Up 1.7 %

The company has a market cap of $831.14 million, a PE ratio of -7.94 and a beta of 1.06. The business’s 50 day moving average price is $17.16 and its 200-day moving average price is $14.57.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. Equities analysts expect that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Insiders Place Their Bets

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $16.42, for a total value of $197,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Samuel Kintz sold 47,709 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $25.04, for a total value of $1,194,633.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the company’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $16.42, for a total transaction of $197,040.00. The disclosure for this sale can be found here. Insiders sold a total of 242,266 shares of company stock valued at $5,391,980 over the last 90 days. 45.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in Enliven Therapeutics in the third quarter worth about $157,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth approximately $66,000. Exchange Traded Concepts LLC lifted its holdings in shares of Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after buying an additional 2,208 shares during the last quarter. AJOVista LLC acquired a new position in shares of Enliven Therapeutics in the fourth quarter valued at $28,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.